Share

Rainbow Children's Medicare Limited Stocks

1149.5Last Updated 02.04.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

₹ 1.26B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
1149.5
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rainbow Children's Medicare Limited operates a multi-specialty pediatric and obstetrics, and gynecology hospital chain in India. The company's child health services include general pediatrics, neonatalogy, surgery, gastroenterology and liver diseases, hematology and oncology, psychology, dentistry, pulmonology, endocrinology, nephrology, nutrition, psychiatry, ENT, cardiology, radiology, physiotherapy and rehabilitation, orthopedics, urology, ophthalmology, dermatology, allergy, neurosurgery, rheumatology, infectious disease, and cranio-maxillofacial surgery; intensive care unit, bone marrow transplant unit, anesthesia and pain management, kidney transplant, cochlear implant services; genetics and metabolic medicines; and laboratory, speech and language therapy, occupational therapy, pediatric and metabolic medicine, developmental and behavioral pediatrics, cerebral palsy care services. Its women health services include obstetrics and gynecology, painless delivery and labor, high risk pregnancy, pregnancy and delivery, childbirth preparation classes, vaginal birth after cesarean, breast feeding support, well women checkup, urogynecology, pre-pregnancy health checkup, minimally invasive surgery, breast care, fetal medicine, menopausal treatment, new-born care, women's nutrition, and diabetology. The company also provides fertility care services, such as fertility treatment, ovulation induction, intracytoplasmic sperm injection treatment, investigation, intrauterine insemination, intracytoplasmic morphologically selected sperm injection, assisted hatching, cryopreservation, sperm and oocyte donor treatments, frozen embryo transfer, surgical sperm retrieval, embryo donor treatments, reproductive surgery, pre-conception counselling, and andrology and urology. As of December 31, 2021, it operated 14 hospitals and 3 clinics in 6 cities with a total of 1,500 beds. The company was incorporated in 1998 and is based in Hyderabad, India.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of RAINBOW.NS is 1772 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks